logo
Plus   Neg
Share
Email

Genentech: Tecentriq, Avastin Combination Study Meets Co-primary Endpoints

Genentech, a member of the Roche Group (RHHBY), said Tecentriq in combination with Avastin, as a treatment for people with unresectable hepatocellular carcinoma who have not received prior systemic therapy, showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with standard-of-care sorafenib in a Phase III IMbrave150 study. Safety data for the combination was consistent with the safety profiles of the individual medicines.

In July 2018, the U.S. FDA granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin in hepatocellular carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT